Additionally, the 36-month beta value for MIRM is 1.10. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MIRM is 37.92M and currently, short sellers hold a 23.46% ratio of that float. The average trading volume of MIRM on June 17, 2024 was 510.82K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MIRM) stock’s latest price update
The stock price of Mirum Pharmaceuticals Inc (NASDAQ: MIRM) has jumped by 15.65 compared to previous close of 25.92. Despite this, the company has seen a gain of 17.32% in its stock price over the last five trading days. benzinga.com reported 2024-06-17 that Monday, Mirum Pharmaceuticals Inc. MIRM announced interim results from two Phase 2b studies evaluating volixibat for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).
MIRM’s Market Performance
MIRM’s stock has risen by 17.32% in the past week, with a monthly rise of 21.12% and a quarterly rise of 15.38%. The volatility ratio for the week is 4.95% while the volatility levels for the last 30 days are 4.39% for Mirum Pharmaceuticals Inc The simple moving average for the past 20 days is 18.10% for MIRM’s stock, with a 6.97% simple moving average for the past 200 days.
Analysts’ Opinion of MIRM
Many brokerage firms have already submitted their reports for MIRM stocks, with Stifel repeating the rating for MIRM by listing it as a “Buy.” The predicted price for MIRM in the upcoming period, according to Stifel is $48 based on the research report published on April 17, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MIRM reach a price target of $58, previously predicting the price at $60. The rating they have provided for MIRM stocks is “Buy” according to the report published on December 18th, 2023.
JP Morgan gave a rating of “Overweight” to MIRM, setting the target price at $37 in the report published on November 20th of the previous year.
MIRM Trading at 19.20% from the 50-Day Moving Average
After a stumble in the market that brought MIRM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.70% of loss for the given period.
Volatility was left at 4.39%, however, over the last 30 days, the volatility rate increased by 4.95%, as shares surge +23.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.10% upper at present.
During the last 5 trading sessions, MIRM rose by +16.24%, which changed the moving average for the period of 200-days by +12.37% in comparison to the 20-day moving average, which settled at $25.66. In addition, Mirum Pharmaceuticals Inc saw 1.55% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MIRM starting from Ramasastry Saira, who sale 5,000 shares at the price of $25.68 back on Jun 05 ’24. After this action, Ramasastry Saira now owns 0 shares of Mirum Pharmaceuticals Inc, valued at $128,400 using the latest closing price.
BJERKHOLT ERIC, the CHIEF FINANCIAL OFFICER of Mirum Pharmaceuticals Inc, purchase 2,000 shares at $24.80 during a trade that took place back on Mar 27 ’24, which means that BJERKHOLT ERIC is holding 14,000 shares at $49,600 based on the most recent closing price.
Stock Fundamentals for MIRM
Current profitability levels for the company are sitting at:
- -0.47 for the present operating margin
- 0.74 for the gross margin
The net margin for Mirum Pharmaceuticals Inc stands at -0.7. The total capital return value is set at -0.19. Equity return is now at value -83.06, with -31.67 for asset returns.
Based on Mirum Pharmaceuticals Inc (MIRM), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at -0.07. The debt to equity ratio resting at 1.31. The interest coverage ratio of the stock is -14.53.
Currently, EBITDA for the company is -98.33 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 6.37. The receivables turnover for the company is 4.07for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.68.
Conclusion
In conclusion, Mirum Pharmaceuticals Inc (MIRM) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
